Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: Where are we now?

British Journal of Dermatology

Volumn 170, Issue 6, 2014, Pages 1226-1236

  Scarisbrick, J J ^a   Kim, Y H ^b   Whittaker, S J ^c   Wood, G S ^d   Vermeer, M H ^e   Prince, H M ^f   Quaglino, P ^g  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b STANFORD CANCER INSTITUTE   (United States)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; CD27 ANTIGEN; CD30 ANTIGEN; CD7 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 23; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; L SELECTIN; STAT4 PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR GATA 3; TUMOR NECROSIS FACTOR ALPHA; TUMOR MARKER;

AGE; ALOPECIA; ANALYSIS; CANCER PROGNOSIS; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL GROWTH; CELL TRANSFORMATION; CLINICAL FEATURE; COMEDO; DENDRITIC CELL; DISEASE COURSE; DISEASE SPECIFIC SURVIVAL; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMATOID PAPULOSIS; MYCOSIS FUNGOIDES; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PAPULE; PERIPHERAL LYMPHOCYTE; POIKILODERMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; SEX; SEZARY SYNDROME; SKIN CYST; SURVIVAL TIME; TELANGIECTASIA; CANCER GRADING; IMMUNOHISTOCHEMISTRY; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SKIN TUMOR;

BIOMARKERS, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; MYCOSIS FUNGOIDES; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SEZARY SYNDROME; SKIN NEOPLASMS;

EID: 84903174896     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12909     Document Type: Review

References (108)

1. Bradford PT, Devesa SS, Anderson WF, Toro JR,. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113: 5064-73.
2. Weinstock MA, Horn JW,. Mycosis fungoides in the United States-increasing incidence and descriptive epidemiology. JAMA 1988; 260: 42-6.
3. Whittaker SJ, Marsden JR, Spittle M, Russell Jones R,. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003; 149: 1095-107.
4. Criscione VD, Weinstock MA,. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007; 143: 854-9.
5. Korgavkar K, Xiong M, Weinstock M,. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol 2013; 149: 1295-9.
6. Willemze R, Jaffe ES, Burg G, et al,. WHO/EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-85.
7. Olsen E, Vonderheid E, Pimpinelli N, et al,. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-22.
8. van Doorn R, Van Haselen CW, van Voorst Vader PC, et al,. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000; 136: 504-10.
9. Kim YH, Liu HL, Mraz-Gernhard S, et al,. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003; 139: 857-66.
10. Agar NS, Wedgeworth E, Crichton S, et al,. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28: 4730-9.
11. Quaglino P, Pimpinelli N, Berti E, et al,. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer 2012; 118: 5830-9.
12. Talpur R, Singh L, Daulat S, et al,. Long-term outcomes of 1263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res 2012; 18: 5051-60.
13. Bunn PA, Lamberg SI,. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 1979; 63: 725-8.
14. Lamberg SI, Green SB, Byar DP, et al,. Status report of 376 mycosis fungoides patients at 4 years: Mycosis Fungoides Cooperative Group. Cancer Treat Rep 1979; 63: 701-7.
15. Diamandidou E, Colome M, Fayad L, et al,. Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol 1999; 40: 914-24.
16. Kim YH, Jensen RA, Watanabe GL, et al,. Clinical stage IA (limited patch and plaque) mycosis fungoides: a long-term outcome analysis. Arch Dermatol 1996; 132: 1309-13.
17. de Coninck EC, Kim YH, Varghese A, Hoppe RT,. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 2001; 19: 779-84.
18. Benner MF, Jansen PM, Vermeer MH, Willemze R,. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood 2012; 119: 1643-9.
19. Vonderheid EC, Bernengo MG, Burg G, et al,. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002; 46: 95-106.
20. Scarisbrick JJ, Whittaker S, Evans AV, et al,. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood 2001; 97: 624-30.
21. Vidulich KA, Talpur R, Bassett RL, Duvic M,. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol 2009; 48: 243-52.
22. Kashani-Sabet M, McMillan A, Zackheim HS,. A modified staging classification for cutaneous T-cell lymphoma. J Am Acad Dermatol 2001; 45: 700-6.
23. Marti RM, Estrach T, Reverter JC, Mascarõ JM,. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol 1991; 127: 1511-16.
24. Zackheim HS, Amin S, Kashani-Sabet M, McMillan A,. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 1999; 40: 418-25.
25. Toro JR, Stoll HL Jr, Stomper PC, Oseroff AR,. Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 1997; 37: 58-67.
26. Schmid MH, Bird P, Dummer R, et al,. Tumor burden index as a prognostic tool for cutaneous T-cell lymphoma: a new concept. Arch Dermatol 1999; 135: 1204-8.
27. Stevens SR, Ke MS, Parry EJ, et al,. Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). Arch Dermatol 2002; 138: 42-8.
28. Olsen E, Duvic M, Frankel A, et al,. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376-88.
29. Olsen EA, Kim YH, Kuzel TM, et al,. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-15.
30. Olsen EA, Whittaker S, Kim YH, et al,.; International Society for Cutaneous Lymphomas; United States Cutaneous Lymphoma Consortium; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011; 29: 2598-607.
31. Scarisbrick JJ, Morris S,. How big is your hand and should you use it to score skin in cutaneous T-cell lymphoma? Br J Dermatol 2013; 69: 260-5.
32. Weinstock MA, Reynes JF,. The changing survival of patients with mycosis fungoides. Cancer 1999; 85: 208-12.
33. Suzuki SY, Ito K, Ito M, Kawai K,. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome. J Dermatol Sci 2010; 57: 37-43.
34. van Doorn R, Scheffer E, Willemze R,. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol 2002; 138: 191-8.
35. Gerami P, Rosen S, Kuzel T, et al,. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol 2008; 144: 738-46.
36. Muniesa C, Estrach T, Pujol RM, et al,. Folliculotropic mycosis fungoides: clinicopathological features and outcome in a series of 20 cases. J Am Acad Dermatol 2010; 62: 418-26.
37. Lehman JS, Cook-Norris RH, Weed BR, et al,. Folliculotropic mycosis fungoides: single-center study and systematic review. Arch Dermatol 2010; 146: 607-13.
38. Abbott RA, Sahni D, Robson A, et al,. Poikilodermatous mycosis fungoides: a study of its clinicopathological, immunophenotypic, and prognostic features. J Am Acad Dermatol 2011; 65: 313-19.
39. Basarab T, Fraser-Andrews EA, Orchard G, et al,. Lymphomatoid papulosis in association with mycosis fungoides: a study of 15 cases. Br J Dermatol 1990; 139: 630-8.
40. Marti RM, Pujol RM, Servitje O, et al,. Sézary syndrome and related variants of classic cutaneous T-cell lymphoma. A descriptive and prognostic clinicopathologic study of 29 cases. Leuk Lymphoma 2003; 44: 59-69.
41. Tancrède-Bohin E, Ionescu MA, de La Salmonière P, et al,. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas. Arch Dermatol 2004; 140: 1057-61.
42. + cutaneous lymphomas and early mycosis fungoides. J Invest Dermatol 2012; 132: 703-10.
43. Wasik MA, Vonderheid EC, Bigler RD, et al,. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. Arch Dermatol 1996; 132: 42-7.
44. Vonderheid EC, Pavlov I, Delgado JC, et al,. Prognostic factors and risk stratification in early mycosis fungoides. Leuk Lymphoma 2014; 55: 44-50.
45. Salhany KE, Cousar JB, Greer JP, et al,. Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study. Am J Pathol 1988; 132: 265-77.
46. Vergier B, de Muret A, Beylot-Barry M, et al,. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneous Lymphomas. Blood 2000; 95: 2212-18.
47. Edinger JT, Clark BZ, Pucevich BE, et al,. CD30 expression and proliferative fraction in non-transformed mycosis fungoides. Am J Surg Pathol 2009; 33: 1860-8.
48. Natkunam Y, Warnke RA, Haghighi B, et al,. Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven cases. J Cutan Pathol 2000; 27: 392-9.
49. Hu S, Xu-Monette ZY, Balasubramanyam A, et al,. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013; 121: 2715-24.
50. +, presenting in the skin: an increasingly recognized entity with an aggressive course. J Clin Oncol 2001; 19: 2179-88.
51. Kadin ME,. Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders. Oncology 2009; 23: 1158-64.
52. Nikolaou V, Papadavid E, Katsambas A, et al,. Clinical characteristic and course of CD8+ cytotoxic variant of mycosis fungoides. Br J Dermatol 2009; 161: 826-30.
53. Krejsgaard T, Odum N, Geisler C, et al,. Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome. Leukemia 2012; 26: 424-32.
54. Hallermann C, Schulze HJ, Neumann C, Klemke CD,. The regulatory T-cell phenotype in progressive mycosis fungoides. G Ital Dermatol Venereol 2008; 143: 15-19.
55. Capriotti E, Vonderheid EC, Thoburn CJ, et al,. Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. Leuk Lymphoma 2008; 49: 1190-201.
56. Heid JB, Schmidt A, Oberle N, et al,. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome. J Invest Dermatol 2009; 129: 2875-85.
57. Berger CL, Tigelaar R, Cohen J, et al,. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 2005; 105: 1640-7.
58. Klemke CD, Fritzsching B, Franz B, et al,. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas. Leukemia 2006; 20: 1123-9.
59. Wada DA, Wilcox RA, Weenig RH, Gibson LE,. Paucity of intraepidermal FoxP3-positive T cells in cutaneous T-cell lymphoma in contrast with spongiotic and lichenoid dermatitis. J Cutan Pathol 2010; 37: 535-41.
60. Gjerdrum LM, Woetmann A, Odum N, et al,. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 2007; 21: 2512-18.
61. Tiemessen MM, Mitchell TJ, Hendry L, et al,. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol 2006; 126: 2217-23.
62. Fried I, Cerroni L,. FOXP3 in sequential biopsies of progressive mycosis fungoides. Am J Dermatopathol 2012; 34: 263-5.
63. Vermeer MH, van Doorn R, Dukers D, et al,. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol 2001; 19: 4322-9.
64. Hoppe RT, Medeiros LJ, Warnke RA, Wood GS,. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995; 32: 448-53.
65. Ni X, Hazarika P, Zhang C, et al,. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clin Cancer Res 2001; 7: 2682-92.
66. Stutz N, Johnson RD, Wood GS,. The Fas apoptotic pathway in cutaneous T-cell lymphomas: frequent expression of phenotypes associated with resistance to apoptosis. J Am Acad Dermatol 2012; 67: 1327. e1-e10.
67. Wu J, Nihal M, Siddiqui J, et al,. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol 2009; 129: 1165-73.
68. Wilcox RA, Wada DA, Ziesmer SC, et al,. Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood 2009; 114: 2936-44.
69. Sugaya M, Miyagaki T, Ohmatsu H, et al,. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. J Dermatol Sci 2012; 68: 45-51.
70. Kim EJ, Hess S, Richardson SK, et al,. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005; 115: 798-812.
71. Pardoll DM,. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.
72. Nebozhyn M, Loboda A, Kari L, et al,. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood 2006; 107: 3189-96.
73. Wong HK, Wilson AJ, Gibson HM, et al,. Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides-cutaneous T cell lymphoma. J Invest Dermatol 2006; 126: 212-19.
74. Kiessling MK, Oberholzer PA, Mondal C, et al,. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood 2011; 117: 2433-40.
75. Samimi S, Benoit B, Evans K, et al,. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol 2010; 146: 1382-8.
76. Wada DA, Wilcox RA, Harrington SM, et al,. Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and Sézary syndrome. Am J Hematol 2011; 86: 325-7.
77. Cetinözman F, Jansen PM, Willemze R,. Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma. Am J Surg Pathol 2012; 36: 109-16.
78. Fierro MT, Ponti R, Titli S, et al,. TCRγ-chain gene rearrangement by GeneScan: incidence and significance of clonal heterogeneity in Sézary syndrome. J Invest Dermatol 2010; 130: 2312-19.
79. Bernengo MG, Quaglino P, Novelli M, et al,. Prognostic factors in Sézary syndrome: a multivariate analysis of clinical, haematological and immunological features. Ann Oncol 1998; 9: 857-63.
80. Vonderheid EC, Bernengo MG,. The Sézary syndrome: hematologic criteria. Hematol Oncol Clin North Am 2003; 17: 1367-89.
81. Jones D, Dang NH, Duvic M, et al,. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol 2001; 115: 885-92.
82. Bernengo MG, Novelli M, Quaglino P, et al,. The relevance of the CD4+CD26- subset in the identification of circulating Sézary cells. Br J Dermatol 2001; 144: 125-35.
83. Introcaso CE, Hess SD, Kamoun M, et al,. Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sézary syndrome. J Am Acad Dermatol 2005; 53: 428-34.
84. Kelemen K, Guitart J, Kuzel TM, et al,. The usefulness of CD26 in flow cytometric analysis of peripheral blood in Sézary syndrome. Am J Clin Pathol 2008; 129: 146-56.
85. Novelli M, Savoia P, Fierro MT, et al,. Keratinocytes express dipeptidyl-peptidase IV (CD26) in benign and malignant skin diseases. Br J Dermatol 1996; 134: 1052-6.
86. Wong HK, Mishra A, Hake T, Porcu P,. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). Br J Haematol 2010; 155: 150-66.
87. Dulmage BO, Geskin LJ,. Lessons learned from gene expression profiling of cutaneous T-cell lymphoma. Br J Dermatol 2013; 169: 1188-97.
88. Vowels BR, Lessin SR, Cassin M, et al,. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 1994; 103: 669-73.
89. Chong BF, Wilson AJ, Gibson HM, et al,. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides. Clin Cancer Res 2008; 14: 646-53.
90. Scarisbrick J, Mitchell T, Calonje E, et al,. Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides. J Invest Dermatol 2003; 121: 894-901.
91. Salgado R, Servitje O, Gallardo F, et al,. Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. J Invest Dermatol 2010; 130: 1126-35.
92. van Kester MS, Borg MK, Zoutman WH, et al,. A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides. J Invest Dermatol 2012; 132: 2050-9.
93. Litvinov IV, Jones DA, Sasseville D, Kupper TS,. Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma. Clin Cancer Res 2010; 16: 2106-14.
94. Booken N, Gratchev A, Utikal J, et al,. Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia 2008; 22: 393-9.
95. Campbell JJ, Clark RA, Watanabe R, Kupper TS,. Sézary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010; 116: 767-71.
96. Poszepczynska-Guigné E, Schiavon V, D'Incan M, et al,. CD158k/KIR3DL2 is a new phenotypic marker of Sézary cells: relevance for the diagnosis and follow-up of Sézary syndrome. J Invest Dermatol 2004; 122: 820-3.
97. Su MW, Dorocicz I, Dragowska WH, et al,. Aberrant expression of T-plastin in Sézary cells. Cancer Res 2003; 63: 7122-7.
98. Tang N, Gibson H, Germeroth T, et al,. T-plastin (PLS3) gene expression differentiates Sézary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression. Br J Dermatol 2010; 162: 463-6.
99. Jones CL, Ferreira S, McKenzie RC, et al,. Regulation of T-plastin expression by promoter hypomethylation in primary cutaneous T-cell lymphoma. J Invest Dermatol 2012; 132: 2042-9.
100. Shipp MA,. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has 'high-risk' disease? Blood 1994; 83: 1165-73.
101. Solal-Céligny P, Roy P, Colombat P, et al,. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-65.
102. Dippel E, Goerdt S, Assaf C, et al,. Cutaneous T-cell lymphoma severity index and T-cell gene rearrangement. Lancet 1997; 350: 1776-7.
103. Klemke CD, Mansmann U, Poenitz N, et al,. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome. Br J Dermatol 2005; 153: 118-24.
104. Evans KG, Troxel AB, DeNardo BJ, et al,. Validity assessment of the cutaneous T-cell lymphoma severity index to predict prognosis in advanced mycosis fungoides/Sézary syndrome. J Am Acad Dermatol 2011; 64: 682-9.
105. Benton E, Crichton S, Talpur R, et al,. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sézary syndrome. Eur J Cancer 2013; 49: 2859-68.
106. Trautinger F, Knobler R, Willemze R, et al,. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006; 42: 1014-30.
107. Duarte RF, Canals C, Onida F, et al,. Allogeneic haematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome. J Clin Oncol 2010; 28: 4492-9.
108. Prince HM,. Are we close to a prognostic index for cutaneous T cell lymphoma? Leuk Lymphoma 2014; 55: 7-8.